Capricor Therapeutics, Inc. CAPR 深 沪
等待开盘 08-10 09:30:00 美东时间
4.09
-0.090
-2.15%
华盛通- 最 高4.70
- 今 开4.16
- 成交量 635.77万股
- 最 低 3.845
- 昨 收 4.18
- 总市值 9.95万
- 52周最高 40.37
- 市盈率 静 --
- 换手率 26137.18%
- 52周最低 0.00
- 委 比 -26.97%
- 总股本 2.43万
- 历史最高 171.50
- 量 比 0.68
- 振 幅 20.45%
- 历史最低 0.00
- 每 手 1
- 风险率 10.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Communication services up 2.5%, energy down 1.84%.
07-27 22:21
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents
Capricor Therapeutics fell over 60% Monday after the FDA posted briefing documents ahead of the company's July 29 advisory committee meeting.
07-27 21:19
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review
Capricor Therapeutics shares are trading higher Tuesday as the FDA resumed Deramiocel BLA review with a new PDUFA date of August 22, 2026.
03-10 22:47
Martin Shkreli Takes Aim At Capricor — Stock Sinks
Capricor Therapeutics stock plummets after Martin Shkreli announces he is shorting the stock.
2025-11-25 02:49
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics announced positive four-year safety and efficacy results for Deramiocel in treating Duchenne muscular dystrophy (DMD), showing preservation of cardiac function, slowed disease progression, and a favorable safety profile. Results were presented at PPMD’s 2025 Annual Conference.
2025-06-20 13:25
Capricor Therapeutics盘中异动 急速拉升5.04%
北京时间2024年12月03日03时56分，Capricor Therapeutics, Inc.（CAPR.us）股票出现异动，股价快速拉升5.04%。截至发稿，该股报19.97美元/股，成交量99.1132万股，换手率2.18%，振幅7.47%。 最近的财报数据显示，该股实现营业收入2.26百万美元，净利润-12.56百万美元，每股收益-0.38美元，毛利1.90百万美元，市盈率-19.55倍。 机构评级方面，在所有7家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。 Capricor Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.05...
2024-12-03 03:56
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones i...
2024-09-26 02:49
